PubMed=9384677
Guckel B., Lindauer M., Rudy W., Habicht A., Siebels M., Kaul S., Bastert G., Meuer S.C., Moebius U.
CD80-transfected human breast and ovarian tumor cell lines: improved immunogenicity and induction of cytolytic CD8+ T lymphocytes.
Cytokines Mol. Ther. 1:211-221(1995)

PubMed=10359208; DOI=10.1038/sj.cgt.7700050
Guckel B., Meyer G.C., Rudy W., Batrla R., Meuer S.C., Bastert G., Wallwiener D., Moebius U.
Interleukin-12 requires initial CD80-mediated T-cell activation to support immune responses toward human breast and ovarian carcinoma.
Cancer Gene Ther. 6:228-237(1999)

PubMed=10359214; DOI=10.1038/sj.cgt.7700054
Meyer G.C., Batrla R., Rudy W., Meuer S.C., Wallwiener D., Guckel B., Moebius U.
Potential of CD80-transfected human breast carcinoma cells to induce peptide-specific T lymphocytes in an allogeneic human histocompatibility leukocyte antigens (HLA)-A2.1+-matched situation.
Cancer Gene Ther. 6:282-288(1999)

PubMed=15365776; DOI=10.1007/s00262-004-0583-z; PMCID=PMC11034349
Guckel B., Stumm S., Rentzsch C., Marme A., Mannhardt G., Wallwiener D.
A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.
Cancer Immunol. Immunother. 54:129-140(2005)